Disrupting Dengue with an Emerging Markets Launch Strategy

Published 26 Sep 2016
Reference 6212
Topic Operations
Industry Biotechnology
Region Global
Length 22 page(s)
Language English

Sanofi Pasteur’s newly approved dengue vaccine, Dengvaxia, was unusual in that it was launched in the Philippines and other at-risk countries. By choosing to “flip the model” – launch in an emerging market setting as opposed to developed markets – it had to overcome various obstacles across the value chain, from registration to financing to supply. The company spent 20 years and invested $1.7 billion to develop Dengvaxia, taking several high-risk decisions and making trade-offs along the way. The case highlights the stakeholder interdependencies and uncertainties that remained as the vaccine implementation programme crept closer. If successfully resolved, it could potentially offer a blueprint for others.

Teaching objectives

The case explores a new business model for launching a vaccine. It can be used to discuss the stakeholder network involved in vaccine adoption decisions, the opportunities and challenges of launching a vaccine in an emerging market setting, the role of public health decision-making in managing the burden of infectious diseases in low- and middle-income countries, and the contributions of the private sector in addressing their healthcare needs.

  • Public health
  • Infectious disease control
  • Vaccination program
  • Vaccine
  • Vaccine adoption
  • Infectious disease management
  • Global health
  • Public health
  • Emerging markets
  • Bottom of the pyramid
  • Health care innovation
  • Health sector stakeholders
  • Risk management
  • New product development
  • Q11617
  • HMI
  • Pharmaceutical and Medical Device Sectors